双膦酸盐与地舒单抗在髋部骨折后痴呆或衰弱人群中的有效性:多数据库队列研究
该多国平行人群队列研究纳入髋部骨折后60天内启用双膦酸盐或地舒单抗的≥50岁人群,比较后续骨折与死亡风险。双膦酸盐组任何后续骨折发生率较高(sHR 1.16;95% CI 1.11-1.21),男性更高(sHR 1.27;95% CI 1.15-1.42),女性未达统计学显著(sHR 1.23;95% CI 1.00-1.52);男性双膦酸盐使用者死亡率较低(HR 0.90;95% CI 0.81-0.99)。痴呆或衰弱状态间无显著差异。
要点
- 双膦酸盐较地舒单抗任何后续骨折发生率更高(sHR 1.16;95% CI 1.11-1.21)。
- 男性双膦酸盐使用者死亡率低于地舒单抗使用者(HR 0.90;95% CI 0.81-0.99)。
- 痴呆或衰弱状态间无显著差异,性别可能影响抗骨吸收药物选择。
核心结论
- 双膦酸盐使用者任何后续骨折发生率高于地舒单抗使用者(sHR 1.16;95% CI 1.11-1.21)。
- 男性双膦酸盐使用者死亡率低于地舒单抗使用者(HR 0.90;95% CI 0.81-0.99)。
- 痴呆和衰弱状态间无显著差异。
研究设计与样本
- 在澳大利亚、香港、台湾和英国开展的平行人群队列研究。
- 纳入≥50岁、首次髋部骨折出院后60天内处方或配发双膦酸盐或地舒单抗者。
- 对痴呆、衰弱、女性和男性进行亚组分析。
- 采用逆概率治疗加权Cox和竞争风险模型估计HR和sHR及95%CI,并用Meta分析合并各辖区结果。
主要发现
- 双膦酸盐使用者18292例,地舒单抗使用者8560例。
- 双膦酸盐 vs 地舒单抗第二次髋部骨折sHR 1.13(95% CI 0.76-1.69),死亡率HR 0.99(95% CI 0.94-1.04)。
- 双膦酸盐 vs 地舒单抗任何后续骨折sHR 1.16(95% CI 1.11-1.21)。
- 男性任何后续骨折sHR 1.27(95% CI 1.15-1.42),女性sHR 1.23(95% CI 1.00-1.52)未达统计学显著。
- 男性双膦酸盐使用者死亡率HR 0.90(95% CI 0.81-0.99),低于地舒单抗使用者。
临床怎么用
- 原文未据此给出推荐,仅指出性别可能影响抗骨吸收治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Brief rationale: The effectiveness of bisphosphonates versus denosumab after hip fracture, especially in people with dementia or frailty, remains unclear. MAIN RESULT: Bisphosphonates were associated with a higher rate of subsequent fracture and a lower mortality rate in men. There are no differences by dementia or frailty status. Significance of the paper: Sex may influence antiresorptive treatment choice. PURPOSE: The relative effectiveness of first-line antiresorptive medications post-hip fracture in people with dementia or frailty is not understood. We investigated the risk of a subsequent fracture and death in people prescribed bisphosphonates or denosumab following hip fracture, including in people with dementia and frailty. METHODS: Parallel population-based cohort studies were conducted in Australia, Hong Kong, Taiwan, and the United Kingdom. People aged ≥ 50 prescribed or dispensed a bisphosphonate or denosumab within 60 days of discharge following their first hip fracture were included. Subgroup analyses were conducted for people with dementia, frailty, women, and men. Outcomes were second hip fracture, any subsequent fracture, and death. Inverse probability of treatment weighted Cox and competing risk models were used to estimate hazard ratios (HR) and subdistribution hazard ratios (sHRs) with 95% confidence intervals (CIs) for outcomes. Results across jurisdictions were combined using meta-analyses. RESULTS: There were 18,292 bisphosphonate users and 8560 denosumab users. Bisphosphonates versus denosumab were associated with similar rates of second hip fracture (sHR 1.13; 95% CI 0.76-1.69) and mortality (HR 0.99; 95% CI 0.94-1.04), but higher rates of any subsequent fracture (sHR 1.16; 95% CI 1.11-1.21), including in men (sHR1.27; 95% CI 1.15-1.42) but not in women (sHR 1.23; 95% CI 1.00-1.52), or in people with dementia or frailty. Men who used bisphosphonates had lower rates of mortality (HR 0.90; 95% CI 0.81-0.99) than men who used denosumab. CONCLUSION: Bisphosphonate users had higher rates of subsequent fracture than denosumab users. Mortality rates in men were lower with bisphosphonates than denosumab. There were no significant differences by dementia and frailty status.
引用
- Ilomäki J, Wood SJ, Tan GSQ, et al. The effectiveness of bisphosphonates vs denosumab in people with dementia or frailty post hip fracture: a multi-database cohort study. Osteoporos Int. 2025. PMID: 41353478. doi:10.1007/s00198-025-07676-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。